AI coach aims to close the hepatitis b treatment gap

NCT ID NCT07520123

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests an AI-powered assistant (Union-Agent) designed to encourage people with chronic hepatitis B who have been diagnosed but not yet treated to start antiviral medication. The study will enroll 2000 adults in China who are eligible for treatment but haven't started. The AI provides education, medication reminders, symptom tracking, and referral suggestions. The goal is to see if this approach can increase the number of patients who begin antiviral therapy within six months by at least 50% compared to current rates.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Intelligent-agent (Union-Agent) delivering education, reminders, follow-up, and referral suggestions

What this could lead to

If successful, this could show that an AI assistant can significantly increase the number of hepatitis B patients who start antiviral treatment, helping more people manage their condition.

What could go wrong

This is an early-stage study with no control group, so improvements may be due to other factors. The AI tool requires smartphone use, which may not work for all patients.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic hepatitis B virus infection hepatitis B virus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Department of Infectious Disease, Wuhan Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, 430022, China